Chugai Pharmaceutical Co - Public Comps and Valuation Multiples

Chugai Pharmaceutical Co Overview

About Chugai Pharmaceutical Co

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.

Founded

1943

HQ

Employees

7.8K+

Website

chugai-pharm.co.jp

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $7.9B

LTM EBITDA $4.0B

EV

$82.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Chugai Pharmaceutical Co Financials

As of October 2025, Chugai Pharmaceutical Co reported last 12-month revenue of $7.9B and EBITDA of $4.0B.

In the same period, Chugai Pharmaceutical Co generated $5.6B in LTM gross profit and $2.7B in net income.

See Chugai Pharmaceutical Co valuation multiples based on analyst estimates

Chugai Pharmaceutical Co P&L

In the most recent fiscal year, Chugai Pharmaceutical Co reported revenue of $7.5B and EBITDA of $3.5B.

Chugai Pharmaceutical Co expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Chugai Pharmaceutical Co valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$7.9B	XXX	$7.5B	XXX	XXX	XXX
Gross Profit	$5.6B	XXX	$5.3B	XXX	XXX	XXX
Gross Margin	71%	XXX	71%	XXX	XXX	XXX
EBITDA	$4.0B	XXX	$3.5B	XXX	XXX	XXX
EBITDA Margin	51%	XXX	46%	XXX	XXX	XXX
EBIT	$3.8B	XXX	$3.5B	XXX	XXX	XXX
EBIT Margin	48%	XXX	46%	XXX	XXX	XXX
Net Profit	$2.7B	XXX	$2.5B	XXX	XXX	XXX
Net Margin	35%	XXX	33%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Chugai Pharmaceutical Co including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $7.9B. EBITDA for the last twelve months was $4.0B. In the most recent fiscal year, Chugai Pharmaceutical Co achieved $7.5B in revenue and $3.5B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$7.9B	Analyst estimates available to subscribers	$7.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$5.6B	Analyst estimates available to subscribers	$5.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	71.1% gross margin	Analyst estimates available to subscribers	71.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$4.0B	Analyst estimates available to subscribers	$3.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	50.9% EBITDA margin	Analyst estimates available to subscribers	46.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$3.8B	Analyst estimates available to subscribers	$3.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	48.1% EBIT margin	Analyst estimates available to subscribers	46.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$2.7B	Analyst estimates available to subscribers	$2.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	34.9% net profit margin	Analyst estimates available to subscribers	33.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Chugai Pharmaceutical Co

This financial data table provides comprehensive performance metrics for Chugai Pharmaceutical Co, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Chugai Pharmaceutical Co generated $7.9B in revenue over the last twelve months.
The company achieved $4.0B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $5.6B.
Net income over the last twelve months reached $2.7B.

Fiscal Year Performance

In the most recent fiscal year, Chugai Pharmaceutical Co reported $7.5B in total revenue.
Fiscal year EBITDA was $3.5B.
The company maintained a gross profit margin of 71.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 46.3%.
Net profit margin reached 33.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Chugai Pharmaceutical Co. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Chugai Pharmaceutical Co Stock Performance

Chugai Pharmaceutical Co has current market cap of JPY 13.77T (or $87.9B), and EV of JPY 12.89T (or $82.2B).

Market Cap Evolution

Chugai Pharmaceutical Co Stock Data

As of November 25, 2025, Chugai Pharmaceutical Co's stock price is JPY 8368 (or $53).

See Chugai Pharmaceutical Co trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$82.2B	$87.9B	XXX	XXX	XXX	XXX	$1.67

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Chugai Pharmaceutical Co Valuation Multiples

Chugai Pharmaceutical Co's trades at 11.0x EV/Revenue multiple, and 23.8x EV/EBITDA.

See valuation multiples for Chugai Pharmaceutical Co and 15K+ public comps

Chugai Pharmaceutical Co Financial Valuation Multiples

As of November 25, 2025, Chugai Pharmaceutical Co has market cap of $87.9B and EV of $82.2B.

Equity research analysts estimate Chugai Pharmaceutical Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Chugai Pharmaceutical Co has a P/E ratio of 32.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$87.9B	XXX	$87.9B	XXX	XXX	XXX
EV (current)	$82.2B	XXX	$82.2B	XXX	XXX	XXX
EV/Revenue	10.4x	XXX	11.0x	XXX	XXX	XXX
EV/EBITDA	20.5x	XXX	23.8x	XXX	XXX	XXX
EV/EBIT	21.7x	XXX	23.8x	XXX	XXX	XXX
EV/Gross Profit	14.7x	XXX	n/a	XXX	XXX	XXX
P/E	32.0x	XXX	35.6x	XXX	XXX	XXX
EV/FCF	38.0x	XXX	32.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chugai Pharmaceutical Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Chugai Pharmaceutical Co Margins & Growth Rates

Chugai Pharmaceutical Co's last 12 month revenue growth is 5%

Chugai Pharmaceutical Co's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.2M for the same period.

Chugai Pharmaceutical Co's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chugai Pharmaceutical Co's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Chugai Pharmaceutical Co and other 15K+ public comps

Chugai Pharmaceutical Co Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	5%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	51%	XXX	46%	XXX	XXX	XXX
EBITDA Growth	8%	XXX	19%	XXX	XXX	XXX
Rule of 40	45%	XXX	52%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	65%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	25%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial